相关实验视频
Updated: Jun 15, 2025
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
33.0K
唐纳作为KCNQ2-和KCNQ3-相关自闭症的新疗法潜力
Andreea Nissenkorn1,2,3, Lior Bar4, Ariel Ben-Bassat4
1Pediatric Neurology Unit, Edith Wolfson Medical Center, Holon, Israel.
Frontiers in cellular neuroscience
|August 23, 2024
概括
多尼佩西尔抑制神经元M电流,为导致发育性脑病变和自闭症的KCNQ2/KCNQ3基因变异提供了潜在的治疗方法. 这项研究表明donepezilzil.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- KCNQ2/KCNQ3基因变异导致功能获取 (GoF) 突变,导致发育性脑病变和自闭症.
- 目前对GoF变异的治疗方法有限,需要新的治疗方法.
- 作为阿尔茨海默氏症药物,多尼佩西尔正在研究其调节M电流的潜力.
研究的目的:
- 为了研究donepezil对M电流的影响在体外.
- 评估donepezil在改善KCNQ2/KCNQ3 GoF变种儿童的认知症状方面的疗效.
主要方法:
- 全细胞补丁电生理学在培养的小鼠海马神经元中测量M电流抑制和自发发射.
- 使用CARS-2,ABAS-II,CDI和CGI-c对四名患有KCNQ2/KCNQ3GoF变异的儿童进行临床评估,经过12个月的非标签多尼治疗.
主要成果:
- 多尼佩西尔显著抑制了激发性和抑制性神经元中的M电流,IC50为0.4μM.
- 多尼佩西尔增加了神经元自发发射频率,而这种效果被氨酸阻断.
- 两个患有KCNQ3变异的患者在自闭症症状 (CARS-2,CGI-c) 和认知发育 (CDI) 中出现了临床显著的改善.
结论:
- 多内西尔显示出作为KCNQ2/KCNQ3相关的发育性脑病变的治疗药物的潜力.
- 重置donepezil为影响M电流的GoF变体提供了一个新的治疗策略.
- 需要进一步的研究,以探索donepezil在这种患者群体中的长期疗效和安全性.
相关概念视频
01:19Autism Spectrum Disorder
77
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
77
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239